TheraRadar
← Back
Data updated: Jun 28, 2026

DANCO LABS LLC

Pharma

DANCO LABS LLC is a pharmaceutical company focused on Metabolic.

2000
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

DANCO LABS LLC's Key Drugs

DANCO LABS LLC's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

DANCO LABS LLC's Recent FDA Approvals

New NDA/BLA approvals for DANCO LABS LLC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

DANCO LABS LLC's Therapeutic Areas

DANCO LABS LLC's approved drugs and pipeline span 1 therapeutic area, led by Metabolic, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Metabolic 100%
1 drugs

DANCO LABS LLC's Top Competitors

DANCO LABS LLC's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

DANCO LABS LLC Pipeline Snapshot

Active clinical trials for DANCO LABS LLC across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Metabolic pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling